drugset

drugset / Trial / NCT00851929

Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension

NCT00851929 ↗

Phase 2/3 Completed 16 enrolled Medical University of South Carolina Gilead Sciences · collab

NaSingle-groupOpen-labelTreatment

Summary

Hypothesis: Ambrisentan (Letairis ®) is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis

Timeline

Start: 2008-11
Primary completion: 2011-04
Completion: 2011-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ambrisentan	Small molecule	10 mg	—

Indications